Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Craig-Hallum Downgrades Quotient Technology to Hold

Craig-Hallum analyst Chad Bennett downgrades Quotient Technology (NYSE:QUOT) from Buy to Hold.

byBenzinga Newsdesk

August 10, 2022

1 minute read

Craig-Hallum analyst Chad Bennett downgrades Quotient Technology (NYSE:QUOT) from Buy to Hold.

Keefe, Bruyette & Woods Maintains Outperform on Redwood Trust, Lowers Price Target to $8.5

By Benzinga Newsdesk

Today, 10:18 AM

Keefe, Bruyette & Woods analyst Bose George maintains Redwood Trust (NYSE:RWT) with a Outperform and lowers the price target from $9 to $8.5.

RWT

Events
News

Geron To Hold Conference Call For Top-Line Results From IMerge Phase 3 Clinical Trial On Jan. 4, 2023 At 8 a.m. EST

By Michael Horton

Today, 10:18 AM

Geron Corporation (NASDAQ:GERN) today announced that it will host a conference call to discuss top-line results from the IMerge Phase 3 clinical trial of imetelstat, the Company's first-in-class telomerase inhibitor,

GERN

Oracle Says Expects Q3 Revenue Growth Of 21%-23% In Constant Currency

By Michael Horton

Today, 10:18 AM

-Reuters Citing Conference Call

ORCL

SVB Leerink Maintains Outperform on Rocket Pharmaceuticals, Raises Price Target to $66

By Benzinga Newsdesk

Today, 10:18 AM

SVB Leerink analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and raises the price target from $64 to $66.

RCKT

Craig-Hallum Downgrades Quotient Technology to Hold

Related Posts

Keefe, Bruyette & Woods Maintains Outperform on Redwood Trust, Lowers Price Target to $8.5

Geron To Hold Conference Call For Top-Line Results From IMerge Phase 3 Clinical Trial On Jan. 4, 2023 At 8 a.m. EST

Oracle Says Expects Q3 Revenue Growth Of 21%-23% In Constant Currency

SVB Leerink Maintains Outperform on Rocket Pharmaceuticals, Raises Price Target to $66